Resource Type

Journal Article 15

Year

2022 1

2021 1

2020 2

2019 1

2017 2

2015 1

2014 3

2010 1

2009 1

open ︾

Keywords

antiviral 3

COVID-19 2

cirrhosis 2

Antiviral 1

Antiviral therapy 1

Caesarean section 1

Chinese herbal medicine 1

Coronavirus disease 2019 1

Cytokine storm 1

Favipiravir 1

H1N1 subtype 1

IgM-bearing B lymphocyte 1

L-trp-NCA 1

Lung fibrosis 1

Open-label nonrandomized control study 1

SARS-CoV-2 1

Severe acute respiratory syndrome coronavirus 1

antimicrobial proteins / antiviral profiling of bacteriocins / antiviral therapeutics / immunomodulation / nanosensor technology / mutated SARS-CoV-2 1

antiviral drugs 1

antiviral effect 1

open ︾

Search scope:

排序： Display mode:

Direct acting antiviral-induced dynamic reduction of serum

Tung Huynh, Ke-Qin Hu

Frontiers of Medicine 2019, Volume 13, Issue 6,   Pages 658-666 doi: 10.1007/s11684-019-0707-7

Abstract: Direct acting antiviral (DAA) treatments may reduce the elevated α fetoprotein (AFP), but data on how

Keywords： chronic hepatitis C     α fetoprotein     direct acting antiviral treatment     cirrhosis    

HTML PDF Collect

ROUTE DEVELOPMENT, ANTIVIRAL STUDIES, FIELD EVALUATION AND TOXICITY OF AN ANTIVIRAL PLANT PROTECTANT

Frontiers of Agricultural Science and Engineering 2022, Volume 9, Issue 1, doi: 10.15302/J-FASE- 2021390

Abstract: NK0238 exhibited useful antiviral activities against a variety of viruses both in greenhouse and field

Keywords： antiviral plant protectant / antiviral in the greenhouse / field evaluation / l-trp-NCA / synthesis optimization    

HTML PDF Collect

Design, synthesis, and antiviral properties of 2-aryl-1H-benzimidazole-4-carboxamide derivatives

Xianjin LUO, Zhonglü ZHANG, Yutian YANG, Fei XUE, Naiyun XIU, Yuanbin SHE

Frontiers of Chemical Science and Engineering 2009, Volume 3, Issue 3,   Pages 305-309 doi: 10.1007/s11705-009-0021-z

Abstract: Their potent antiviral properties indicated the prospect of new drugs.

Keywords： benzimidazole     coxsackie virus B3     antiviral properties    

HTML PDF Collect

ROUTE DEVELOPMENT, ANTIVIRAL STUDIES, FIELD EVALUATION AND TOXICITY OF AN ANTIVIRAL PLANT PROTECTANT

Wentao XU, Hao TIAN, Hongjian SONG, Yuxiu LIU, Yongqiang LI, Qingmin WANG

Frontiers of Agricultural Science and Engineering   Pages 110-119 doi: 10.15302/J-FASE-2021390

Abstract: NK0238 exhibited useful antiviral activities against a variety of viruses both in greenhouse and field

Keywords： antiviral plant protectant     antiviral in the greenhouse     field evaluation     L-trp-NCA     synthesis optimization    

HTML PDF Collect

Critical roles of chemokines and cytokines in antiviral innate immune responses during rabies virus infection

Ying HUANG, Clement Wesley GNANADURAI, Zhenfang FU

Frontiers of Agricultural Science and Engineering 2017, Volume 4, Issue 3,   Pages 260-267 doi: 10.15302/J-FASE-2016116

Abstract: The innate immune response is the first line of defense against viral invasion and pro-inflammatory chemokines and cytokines have a critical function in the innate immune responses against virus infections. The ability of a rabies virus (RABV) to induce the expression of chemokines and cytokines can lead to viral clearance from the central nervous system (CNS), whereas the ability to evade such expression and activation contributes to virulence and pathogenicity. In this review, the crucial contribution of chemokines/cytokines to clearing RABV from the CNS is discussed, including recruiting leukocytes into the CNS, enhancement of blood brain barrier permeability and activation of various immune cells that are essential for viral clearance. In addition, recombinant RABV expressing cytokines and chemokines can induce elevated innate and adaptive immune responses which result in clearing an established wild-type RABV infection in the CNS.

Keywords： antiviral     blood brain barrier     chemokines and cytokines     innate immunity     rabies virus    

HTML PDF Collect

ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC

Frontiers of Agricultural Science and Engineering 2021, Volume 8, Issue 4,   Pages 603-622 doi: 10.15302/J-FASE -2021397

Abstract: Despite possessing antiviral traits the potential of bacteriocins to combat SARS-CoV-2 infection hasThese antimicrobial peptides have been suggested as effective antiviral therapeutics and therapeuticSpecific attention is given to the antiviral mechanisms of the molecules along with their integrative

Keywords： antimicrobial proteins / antiviral profiling of bacteriocins / antiviral therapeutics / immunomodulation    

HTML PDF Collect

Current recommendations of managing HBV infection in preconception or pregnancy

James S. Park,Calvin Pan

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 158-165 doi: 10.1007/s11684-014-0340-4

Abstract: The emerging data suggest that initiation of antiviral therapy in the beginning of the third trimesterIn order to minimize the fetal exposure to the antiviral medication, antiviral therapy during the pregnancyand after the pregnancy; the risk factors that increase mother-to-child transmission; safety data on antiviral

Keywords： antiviral therapy     Caesarean section     cirrhosis     hepatitis B     immunoprophylaxis     mother-to-child transmission    

HTML PDF Collect

Oral administration of

Sufen ZHAO,Yuanyuan JIA,Weiwei ZHANG,Lili WANG,Yunfei MA,Kedao TENG

Frontiers of Agricultural Science and Engineering 2015, Volume 2, Issue 4,   Pages 318-326 doi: 10.15302/J-FASE-2015080

Abstract: Garlic ( Liliaceae) has been safely used for more than 5000 years, and research on garlic extract is rapidly increasing because of its multiple biological functions. The effects of oral administration of garlic mixture (GM, water-soluble extract) on infectious bursal disease virus (IBDV)-infected specific pathogen free male white leghorn chicken were examined through histopathological, immunohistochemical, and Western blot analyses, and enzyme-linked immunosorbent assay. The results confirmed the protective effects of oral administration of 5 mg·kg BW GM (Group GM1) on bursal lesions after IBDV infection. In particular, protein expression of IBDV in the bursa decreased in Group GM1, indicating that GM administration decreased IBDV replication in the bursa. Furthermore, immunoglobulin M- and A-bearing B lymphocytes significantly increased 7 days post infection in bursae in Group GM1 ( <0.01), suggesting that the oral administration of 5 mg·kg GM offers moderate protection against B cell destruction after IBDV infection. During infection, the concentration of bursal interferon gamma (IFN-g) increased and peaked in Group GM1 earlier than in Group T (IBDV-exposed), demonstrating that GM administration prompted the production of IFN-g to protect against IBDV infection.

Keywords： garlic     infectious bursal disease virus (IBDV)     antiviral effect     IgM-bearing B lymphocyte    

HTML PDF Collect

A brief review of microRNA and its role in PRRSV infection and replication

Xuekun GUO,Wenhai FENG

Frontiers of Agricultural Science and Engineering 2014, Volume 1, Issue 2,   Pages 114-120 doi: 10.15302/J-FASE-2014022

Abstract: replication by multiple ways such as targeting viral genomic RNA, targeting viral receptor and inducing antiviral

Keywords： porcine reproductive and respiratory syndrome virus (PRRSV)     microRNA     antiviral     viral tropism    

HTML PDF Collect

Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide

Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 502-508 doi: 10.1007/s11684-017-0590-z

Abstract:

Although the efficacy of nucleos(t)ide analogue (NA) has been confirmed for treatment of chronic hepatitis B, long-term therapy has been recommended due to the high frequency of off-therapy viral DNA rebound and disease relapse. In this review, the RNA virion-like particles of hepatitis B virus (HBV) are integrated into the life cycle of HBV replication, and the potential significance of serum HBV RNA is systematically described. The production of HBV RNA virion-like particles should not be blocked by NA; in this regard, serum HBV RNA is found to be a suitable surrogate marker for the activity of intrahepatic covalently closed circular DNA (cccDNA), particularly among patients receiving NA therapy. Therefore, the concept of virological response is redefined as persistent loss of serum HBV DNA and HBV RNA. In contrast to hepatitis B surface antigen (HBsAg) that can originate from either the cccDNA or the integrated HBV DNA fragment, serum HBV RNA, with pregenomic RNA origination, can only be transcribed from cccDNA. Therefore, the loss of serum HBV RNA would likely be a promising predicator for safe drug discontinuation. The clinical status of consistent loss of serum HBV RNA accompanied with low serum HBsAg levels might be implicated as a “para-functional cure,” a status nearly close to the functional cure of chronic hepatitis B, to distinguish the “functional cure” characterized as serum HBsAg loss with or without anti-HBs seroconversion.

Keywords： chronic hepatitis B     serum HBV RNA     nucleos(t)ide analogs     virological response     para-functional cure    

HTML PDF Collect

Advances in newly developing therapy for chronic hepatitis C virus infection

Paul J. Pockros

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 166-174 doi: 10.1007/s11684-014-0334-2

Abstract: Increased understanding of the HCV has allowed further development of new direct-acting antiviral (DAA

Keywords： direct-acting antiviral (DAA)     nucleotide polymerase inhibitors     protease inhibitors    

HTML PDF Collect

Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)

Frontiers of Medicine doi: 10.1007/s11684-023-1037-3

Abstract: So far, a few small-molecule antiviral drugs, including nirmatrelvir–ritonavir (Paxlovid), remdesivirpharmacological mechanism and therapeutic effects focusing on mindeudesivir and other small-molecule antiviral

Keywords： COVID-19     antiviral drugs     mindeudesivir    

HTML PDF Collect

The Scientific Foundation of Chinese Herbal Medicine against COVID-19 Perspective

Elaine Lai-Han Leung, Hu-Dan Pan, Yu-Feng Huang, Xing-Xing Fan, Wan-Ying Wang, Fang He, Jun Cai, Hua Zhou, Liang Liu

Engineering 2020, Volume 6, Issue 10,   Pages 1099-1107 doi: 10.1016/j.eng.2020.08.009

Abstract: ago in combating SARS-CoV and other viral infections could be taken as references in today’s antiviral

Keywords： Coronavirus disease 2019     Severe acute respiratory syndrome coronavirus     Chinese herbal medicine     Antiviral    

HTML PDF Collect

Pathogenesis of pandemic H1N1 2009 influenza virus infection and the implication on management

Kelvin Kai-Wang TO FRCPath, Iris Wai-Sum LI FRCP, Ivan Fan-Ngai HUNG FRCP, Vincent Chi-Chung CHENG FRCPath, Kwok-Yung YUEN MD,

Frontiers of Medicine 2010, Volume 4, Issue 2,   Pages 147-156 doi: 10.1007/s11684-010-0030-9

Abstract: The pandemic H1N1 2009 influenza virus has caused the first influenza pandemic of the 21st century, leading to disproportionate fatalities in the low-risk population despite the generally mild nature of the illness. Advances in sci

Keywords： influenza A virus     H1N1 subtype     pandemic     pathogenesis     virulence factors     immunity     management     antiviral    

HTML PDF Collect

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study Article

Qingxian Cai, Minghui Yang, Dongjing Liu, Jun Chen, Dan Shu, Junxia Xia, Xuejiao Liao, Yuanbo Gu, Qiue Cai, Yang Yang, Chenguang Shen, Xiaohe Li, Ling Peng, Deliang Huang, Jing Zhang, Shurong Zhang, Fuxiang Wang, Jiaye Liu, Li Chen, Shuyan Chen, Zhaoqin Wang, Zheng Zhang, Ruiyuan Cao, Wu Zhong, Yingxia Liu, Lei Liu

Engineering 2020, Volume 6, Issue 10,   Pages 1192-1198 doi: 10.1016/j.eng.2020.03.007

Abstract:

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) have been reported in China since December 2019. More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was about 1%–2%. No specific treatment has been reported. Herein, we examined the effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19. Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2–14: 600 mg twice daily) plus interferon (IFN)-α by aerosol inhalation (5 million U twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1–14: 400 mg/100 mg twice daily) plus IFN-α by aerosol inhalation (5 million U twice daily) were included in the control arm. Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups. For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms. A shorter viral clearance time was found for the FPV arm versus the control arm (median (interquartile range, IQR), 4 (2.5–9) d versus 11 (8–13) d, P < 0.001). The FPV arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest imaging. Multivariable Cox regression showed that FPV was independently associated with faster viral clearance. In addition, fewer adverse events were found in the FPV arm than in the control arm. In this open-label before-after controlled study, FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. These preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection.

Keywords： Favipiravir     COVID-19     SARS-CoV-2     Antiviral therapy     Open-label nonrandomized control study    

HTML PDF Collect

Title Author Date Type Operation

Direct acting antiviral-induced dynamic reduction of serum

Tung Huynh, Ke-Qin Hu

Journal Article

ROUTE DEVELOPMENT, ANTIVIRAL STUDIES, FIELD EVALUATION AND TOXICITY OF AN ANTIVIRAL PLANT PROTECTANT

Journal Article

Design, synthesis, and antiviral properties of 2-aryl-1H-benzimidazole-4-carboxamide derivatives

Xianjin LUO, Zhonglü ZHANG, Yutian YANG, Fei XUE, Naiyun XIU, Yuanbin SHE

Journal Article

ROUTE DEVELOPMENT, ANTIVIRAL STUDIES, FIELD EVALUATION AND TOXICITY OF AN ANTIVIRAL PLANT PROTECTANT

Wentao XU, Hao TIAN, Hongjian SONG, Yuxiu LIU, Yongqiang LI, Qingmin WANG

Journal Article

Critical roles of chemokines and cytokines in antiviral innate immune responses during rabies virus infection

Ying HUANG, Clement Wesley GNANADURAI, Zhenfang FU

Journal Article

ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC

Journal Article

Current recommendations of managing HBV infection in preconception or pregnancy

James S. Park,Calvin Pan

Journal Article

Oral administration of

Sufen ZHAO,Yuanyuan JIA,Weiwei ZHANG,Lili WANG,Yunfei MA,Kedao TENG

Journal Article

A brief review of microRNA and its role in PRRSV infection and replication

Xuekun GUO,Wenhai FENG

Journal Article

Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide

Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia

Journal Article

Advances in newly developing therapy for chronic hepatitis C virus infection

Paul J. Pockros

Journal Article

Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)

Journal Article

The Scientific Foundation of Chinese Herbal Medicine against COVID-19

Elaine Lai-Han Leung, Hu-Dan Pan, Yu-Feng Huang, Xing-Xing Fan, Wan-Ying Wang, Fang He, Jun Cai, Hua Zhou, Liang Liu

Journal Article

Pathogenesis of pandemic H1N1 2009 influenza virus infection and the implication on management

Kelvin Kai-Wang TO FRCPath, Iris Wai-Sum LI FRCP, Ivan Fan-Ngai HUNG FRCP, Vincent Chi-Chung CHENG FRCPath, Kwok-Yung YUEN MD,

Journal Article

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Qingxian Cai, Minghui Yang, Dongjing Liu, Jun Chen, Dan Shu, Junxia Xia, Xuejiao Liao, Yuanbo Gu, Qiue Cai, Yang Yang, Chenguang Shen, Xiaohe Li, Ling Peng, Deliang Huang, Jing Zhang, Shurong Zhang, Fuxiang Wang, Jiaye Liu, Li Chen, Shuyan Chen, Zhaoqin Wang, Zheng Zhang, Ruiyuan Cao, Wu Zhong, Yingxia Liu, Lei Liu

Journal Article